enatumab

Phase 2Monoclonal antibody

BBing Han

enatumab is one of 12 small molecule programs targeting Hemolytic Anemia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hemolytic AnemiaNot yet recruiting

Hemolytic AnemiaPhase 2

Not yet recruiting

Competition

Competitive Landscape

12 competitors in Hemolytic Anemia

#DrugCompanyPhaseTrials

Decadron

AAspen Global Incorporated

Neoral

1 3

Imbruvica

PPharmacyclics LLC.

Phase 2

2 4

Fostamatinib Bid

RRigel Pharmaceuticals

Phase 3

2 5

HMPL-523

HHutchison Medipharma Limited

Phase 3

1 6

Fabhalta

Novartis

Preclinical

1 7

Decadron

QQuince Therapeutics S.p.A.

enatumab

1 9

YTS109 Cell

CChina Immunotech (Beijing) Biotechnology Co., Ltd.

Phase 1

3 10

Inaticabtagene Autoleucel

JJuventas Cell Therapy Ltd.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Not yet recruiting

Hemolytic Anemia

NCT07190261

Clinical

Trials by Indication[1]

Hemolytic Anemia1 trial

A Single-arm Phase 2 Prospective Clinical Study of Enatumab in the Treatment of Relapsed/Refractory Warm Antibody Autoimmune Hemolytic Anemia

Not yet recruiting·BBing Han·Phase 2·NCT07190261·3 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for enatumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — enatumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for enatumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bing Han company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: BBing Han

enatumab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Hemolytic Anemia1 trial

References

Drug Info

Quick Facts

Related News